Injectable devices for sustained ocular drug delivery
用于持续眼部药物输送的注射装置
基本信息
- 批准号:EP/R024839/1
- 负责人:
- 金额:$ 106.86万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2018
- 资助国家:英国
- 起止时间:2018 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This Healthcare Impact Partnership will use drug delivery technologies previously invented by us to develop novel, injectable devices to provide targeted, controlled and sustained drug delivery to the inside of the eye. These devices will address unmet clinical needs in two groups of patients. In addition, we will develop sophisticated benchtop and computer models of drug release in the eye, to allow us to speed up development and reduce the amount of animal testing required to use the devices in humans. Over 5.7 million people in the UK are living with sight-threatening eye conditions. These include conditions that can develop as a result of diabetes, macular degeneration and retinal detachment. The current best practice for treatment of the scarring that can follow retinal detachment is injection of silicone oil into the eye to replace the vitreous. It has been proposed that, in addition to the oil, sustained drug delivery could help reduce the development of scarring. We have previously developed technology to achieve controlled, extended release of drugs from silicone oils, and now wish to apply these technologies to silicone oils that are suitable for use in patients. Treatment for other sight-threatening conditions requires patients to have frequent injections of drugs directly into the eye over many years. This can be uncomfortable and inconvenient for patients, places a burden on the healthcare system and is not feasible in developing countries. A small number of drug delivery devices that reduce the number of injections needed are available, but these must either be removed once the drug release is complete, or, if the device is degradable, do not last much longer than standard injections. We have previously developed technology to make drugs into nanoparticles. We will develop a drug delivery system constructed of nanoparticles inside a material that forms a gel when it is injected into the eye. After the drug has been released, the gel would degrade into non-toxic components. The advantages of this over existing devices are that this technology could be tailored in terms of the drug and dosing, and that higher doses will be possible due to the use of nanoparticles. Both of our delivery devices are injectable, and will improve patient outcomes, particularly in developing countries and patients that present late.Our team is multidisciplinary, including academics specialising in ophthalmic biomaterials and drug delivery. A clinical ophthalmologist specialising in drug delivery will ensure that our technologies are suitable for clinical use. We will also engage with patients groups, who will help inform our development strategy. In order to accelerate the technologies towards the production of devices that are suitable for use in patients, we have partnered with a company who manufacture silicone oil products used to treat retinal detachment. With their expertise, we will be able to ensure that we include certain crucial aspects as we develop our technologies, such as how to scale up manufacture from the laboratory to that suitable for commercial use, and the generation of data that is required for the products to gain a licence for clinical use. Another commercial partner specialising in the production of models to replace animal testing will help us optimise our models, and promote their use to other organisations who are interested in reducing animal use. We will apply our silicone oil-based drug release technology to commercially-available oils, ensuring the resulting product has appropriate physical properties to remain functional in the eye, is not toxic, and has optimal drug release. We will also develop our nanoparticle system, optimising physical, drug-release and toxic properties. At the same time, we will develop existing benchtop and computer models so that they will be able to predict drug release from our devices.
该医疗保健影响伙伴关系将使用我们以前发明的药物输送技术来开发新型注射装置,以提供靶向,受控和持续的药物输送到眼睛内部。这些器械将解决两组患者未满足的临床需求。此外,我们将开发复杂的台式和计算机模型的药物释放的眼睛,使我们能够加快发展,并减少所需的动物试验的数量在人类使用的设备。英国有超过570万人患有威胁视力的眼疾。这些疾病包括糖尿病、黄斑变性和视网膜脱离。目前治疗视网膜脱离后瘢痕形成的最佳实践是将硅油注射到眼睛中以替换玻璃体。有人提出,除了油,持续的药物输送可以帮助减少疤痕的发展。我们之前已经开发出了从硅油中实现药物受控缓释的技术,现在希望将这些技术应用于适合患者使用的硅油。其他威胁视力的疾病的治疗需要患者多年来频繁地直接向眼睛注射药物。这对患者来说可能不舒服和不方便,给医疗保健系统带来负担,在发展中国家是不可行的。有少量的药物输送装置可以减少所需的注射次数,但是一旦药物释放完成,这些装置必须被移除,或者如果装置是可降解的,则不会比标准注射持续更长时间。我们以前开发了将药物制成纳米颗粒的技术。我们将开发一种药物输送系统,该系统由纳米颗粒构成,当注入眼睛时,该材料形成凝胶。药物释放后,凝胶将降解为无毒成分。与现有设备相比,这种技术的优势在于,该技术可以根据药物和剂量进行定制,并且由于使用纳米颗粒,更高的剂量将是可能的。我们的两种输送设备都是可注射的,将改善患者的治疗效果,特别是在发展中国家和晚期患者中。我们的团队是多学科的,包括专门从事眼科生物材料和药物输送的学者。专门从事药物输送的临床眼科医生将确保我们的技术适合临床使用。我们还将与患者团体接触,他们将帮助我们制定发展战略。为了加速生产适用于患者的设备的技术,我们与一家生产用于治疗视网膜脱离的硅油产品的公司合作。凭借他们的专业知识,我们将能够确保我们在开发技术时包括某些关键方面,例如如何将生产从实验室扩大到适合商业用途,以及生成产品获得临床使用许可所需的数据。另一家专门生产替代动物试验模型的商业合作伙伴将帮助我们优化模型,并将其推广给其他有兴趣减少动物使用的组织。我们将把基于硅油的药物释放技术应用于市售油,确保所得产品具有适当的物理特性,以保持眼睛的功能,无毒,并具有最佳的药物释放。我们还将开发我们的纳米颗粒系统,优化物理,药物释放和毒性特性。与此同时,我们将开发现有的台式和计算机模型,以便它们能够预测我们设备的药物释放。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Understanding the Degradation of Core-Shell Nanogels Using Asymmetrical Flow Field Flow Fractionation.
- DOI:10.3390/jfb14070346
- 发表时间:2023-06-29
- 期刊:
- 影响因子:4.8
- 作者:
- 通讯作者:
Insights into the internal structures of nanogels using a versatile asymmetric-flow field-flow fractionation method.
- DOI:10.1039/d0na00314j
- 发表时间:2020-10-13
- 期刊:
- 影响因子:4.7
- 作者:Niezabitowska, Edyta;Town, Adam R.;Sabagh, Bassem;Moctezuma, Marissa D. Morales;Kearns, Victoria R.;Spain, Sebastian G.;Rannard, Steve P.;McDonald, Tom O.
- 通讯作者:McDonald, Tom O.
Dual-responsive degradable core-shell nanogels with tuneable aggregation behaviour.
- DOI:10.1039/d1ra07093b
- 发表时间:2022-01-12
- 期刊:
- 影响因子:3.9
- 作者:Gray DM;Town AR;Niezabitowska E;Rannard SP;McDonald TO
- 通讯作者:McDonald TO
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Victoria Kearns其他文献
Sustained-release drug delivery systems
缓释给药系统
- DOI:
10.1038/s41433-024-03134-w - 发表时间:
2024-05-17 - 期刊:
- 影响因子:3.200
- 作者:
Rachel Williams;Helen Cauldbeck;Victoria Kearns - 通讯作者:
Victoria Kearns
Subretinal Injection Under Perfluorocarbon Liquids to Avoid Foveal Dehiscence
全氟化碳液体视网膜下注射以避免中心凹裂开
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
David H W Steel;Brendan Geraghty;Victoria Kearns;Boris Stanzel;David Wong - 通讯作者:
David Wong
Victoria Kearns的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Victoria Kearns', 18)}}的其他基金
Extending the range of tamponades for the delivery of therapeutic agents to treat proliferative vitreoretinopathy
扩大用于治疗增殖性玻璃体视网膜病变的治疗药物输送的填塞范围
- 批准号:
EP/L000458/1 - 财政年份:2013
- 资助金额:
$ 106.86万 - 项目类别:
Research Grant
相似国自然基金
兼捕减少装置(Bycatch Reduction Devices, BRD)对拖网网囊系统水动力及渔获性能的调控机制
- 批准号:32373187
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Achieving Sustained Control of Inflammation to Prevent Post-Traumatic Osteoarthritis (PTOA)
实现炎症的持续控制以预防创伤后骨关节炎 (PTOA)
- 批准号:
10641225 - 财政年份:2023
- 资助金额:
$ 106.86万 - 项目类别:
Quantifying neural variability and learning during real world brain-computer interface use
量化现实世界脑机接口使用过程中的神经变异和学习
- 批准号:
10838152 - 财政年份:2023
- 资助金额:
$ 106.86万 - 项目类别:
Sustained Release of Potent Antiviral Prodrugs for HIV Prevention
持续释放有效的抗病毒前药以预防艾滋病毒
- 批准号:
10617540 - 财政年份:2023
- 资助金额:
$ 106.86万 - 项目类别:
Remote STATE training for Insomnia in Older Adults
针对老年人失眠的远程 STATE 培训
- 批准号:
10393889 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别:
Remote STATE training for Insomnia in Older Adults
针对老年人失眠的远程 STATE 培训
- 批准号:
10693814 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别:
Implementation of a diabetes navIgator to Mitigate disPArities and improve CGM upTake and sustained use across the lifespan of T1D (IMPACT T1D)
实施糖尿病导航仪以减少差异并提高 CGM 的采用率以及在 T1D 整个生命周期中的持续使用 (IMPACT T1D)
- 批准号:
10708086 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别:
Exploring Developmental Neural Mechanism of Gaze Behaviors during Parent-Child Play
探索亲子游戏中注视行为的发育神经机制
- 批准号:
10433184 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别:
Online EZY Tai Chi: Simplified 8-Form Program for Individuals with Intellectual Disabilities
在线 EZY 太极拳:针对智力障碍人士的简化 8 式课程
- 批准号:
10620736 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别:
3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosis
持续和分阶段释放抗生素和益生菌支架的 3D 生物打印用于治疗细菌性阴道病
- 批准号:
10420527 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别:
Sustained Triumvirate Delivery by Contact Lens for Post-Surgical Management
通过隐形眼镜进行持续三效治疗以进行术后管理
- 批准号:
10383014 - 财政年份:2022
- 资助金额:
$ 106.86万 - 项目类别: